A 12-Week Open-Label Extension Study to Evaluate TNX-102 SL Taken Daily at Bedtime in Patients With PTSD
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2018
At a glance
- Drugs Cyclobenzaprine (Primary)
- Indications Post-traumatic stress disorders
- Focus Adverse reactions
- Sponsors Tonix Pharmaceuticals Inc
- 01 Oct 2018 Status changed from recruiting to discontinued.
- 03 Apr 2018 Status changed from not yet recruiting to recruiting.
- 18 Apr 2017 New trial record